Remote Monitoring and Symptom Management Digital Application
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ASSIST phone application.
- Who it may be relevant to
- Registry conditions: Breast Cancer (Locally Advanced or Metastatic), Lymphoma, Colorectal Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Pilot Randomized Controlled Trial of a Remote Monitoring and Symptom Management Intervention (ASSIST) Among Patients Receiving Systemic Therapy
Overview
The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment. The main question\[s\] it aims to answer are: Is ASSIST feasible for patients (meaning can it be used by patients)? Is ASSIST acceptable to patients (meaning do patients like it)? Researchers will compare the ASSIST phone application to see how it compares to usual clinical care. Participants on the ASSIST arm will use the ASSIST phone application for 12 weeks, and participants in both groups will complete surveys.
Interventions
- Other ASSIST phone application
The intervention consists of a smartphone-based application that provides personalized support using AI during cancer treatment. Patients will also receive standard care from their oncology team, including routine symptom management and supportive care measures.
Primary outcome measures
- Recruitment Rates [Time frame: From enrollment to end of intervention at 12 weeks]
- Percentage of participants using the digital application once per week in at least 7/12 weeks [Time frame: From enrollment to end of intervention at 12 weeks]
Secondary outcome measures (1)
- Acceptability [Time frame: From enrollment to the end of the intervention at 12 weeks]
Eligibility criteria
Inclusion criteria
- Age 18 years or older
- Ability to understand English
- About to begin definitive systemic treatment (or within 4 weeks of beginning treatment) based upon the oncology treatment intent form for a new diagnosis of breast cancer, colorectal cancer, or lymphoma.
- Expected treatment duration of at least 12 weeks
- Own or willing to receive a smartphone
Exclusion criteria
- Cognitive impairment that would interfere with ability to use smartphone application (as assessed by their attending physician)
- Visual or motor impairment that would prevent smartphone use
- Expected survival less than 3 months
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Supportive care
Study locations
United States · 1 center
- Massachusetts General Hospital — Boston
Identifiers
NCT: NCT07553572 · 25-739